Functional imaging modalities (positron emission tomography, single photon emission tomography, magnetic resonance spectroscopy, and functional magnetic resonance) allow aspects of regional cerebral function to be evaluated in various neuropsychiatric disorders. This review will summarize the use of such techniques in current imaging studies involving Parkinson’s disease and dementia with Lewy bodies, with respect to assessing regional changes, using them in differential diagnosis, and monitoring disease progression and treatment effects. (J Geriatr Psychiatry Neurol 2004; 17:158-163)
1. Eidelberg D, Moeller JR, Ishikawa T, et al. Early differential diagnosis of Parkinson’s disease with F-18 fluorodeoxyglucose and positron emission tomography. Neurology1995; 45:1995-2004.
2.
2. Mohr E, Mann UM, Miletich RS, et al. Neuropsychological and glucose metabolic profiles in asymmetric Parkinson’s disease. Can J Neurol Sci1992; 19:163-169.
3.
3. Wolfson LI, Leenders KL, Brown LL, Jones T.Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson’s disease. Neurology1985; 35:1399-1405.
4.
4. Berding G, Odin P, Brooks DJ, et al. Resting regional cerebral glucose metabolism in advanced Parkinson’s disease studied in the off and on conditions with F-18 FDG-PET. Mov Disord2001; 16:1014-1022.
5.
5. Ito K, Morrish PK, Rakshi JS, et al. Statistical parametric map-ping with F-18-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson’s disease. J Neurol Neurosurg Psychiatry1999; 66:754-758.
6.
6. Lucignani G, Gobbo C, Moresco RM, et al. The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using C-11-2-beta-carbomethoxy-3-beta-(4-fluorophenyl)-tropane in patients with movement disorders. Nucl Med Commun2002; 23:1047-1055.
7.
7. Ma Y, Dhawan V, Mentis M, Chaly T, Spetsieris PG, Eidelberg D.Parametric mapping of F-18 FPCIT binding in early stage Parkinson’s disease: a PET study. Synapse2002; 45:125-133.
8.
8. Rinne JO, Nurmi E, Ruottinen HM, Bergman J, Eskola O, Solin O.F-18 FDOPA and F-18 CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson’s disease. Synapse2001; 40:193-200.
9.
9. Antonini A, De Notaris R, Benti R, De Gaspari D, Pezzoli G.Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson’s disease. Neurol Sci2001; 22:45-46.
10.
10. Markus HS, Costa DC, Lees AJ. HMPAO SPECT in Parkinson’s disease before and after levodopa: correlation with dopaminergic responsiveness. J Neurol Neurosurg Psychiatry1994; 57:180-185.
11.
11. Tachibana H, Tomino Y, Kawabata K, Sugita M, Fukuchi M.12-month follow-up study of regional cerebral blood flow in Parkinson’s disease. Dementia1995; 6:89-93.
12.
12. Jagust WJ, Reed BR, Martin EM, Eberling JL, Nelsonabbott RA. Cognitive function and regional cerebral blood flow in Parkinson’s disease. Brain1992; 115:521-537.
13.
13. Abe Y, Kachi T, Kato T, et al. Occipital hypoperfusion in Parkinson’s disease without dementia: correlation to impaired cortical visual processing. J Neurol Neurosurg Psychiatry2003; 74:419-422.
14.
14. Firbank M, Colloby SJ, Burn D, McKeith IG, O’Brien JT. Regional cerebral blood flow in Parkinson’s disease with and without dementia. Neuroimage2003; 20:1309-1319.
15.
15. Imon Y, Matsuda H, Ogawa M, Kogure D, Sunohara N.SPECT image analysis using statistical parametric mapping in patients with Parkinson’s disease. J Nucl Med1999; 40:1583-1589.
16.
16. Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord2000; 15:503-510.
17.
17. Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson’s disease by [123I]FPCIT SPECT. J Nucl Med1999; 40:753-761.
18.
18. Booij J, Tissingh G, Boer GJ, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry1997; 62:133-140.
19.
19. Habraken JB, Booij J, Slomka P, Sokole EB, van Royen EA. Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm. J Nucl Med1999; 40:1091-1097.
20.
20. O’Brien JT, Colloby SJ, Fenwick J, et al. Dopamine transporter loss visualised with FP-CIT SPECT in dementia with Lewy bodies. Arch Neurol In press.
21.
21. Seibyl JP, Marek K, Sheff K, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson’s patients. J Nucl Med1998; 39:1500-1508.
22.
22. Sjoholm H, Sundsfjord J, Mellgren SI. Beta-CIT-SPECT combined with UPDRS appears to distinguish different parkinsonian conditions. Acta Neurol Scand2002; 105:5-7.
23.
23. Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. I-123 beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson’s disease and multiple system atrophy. Mov Disord2001; 16:1023-1032.
24.
24. Walker Z, Costa DC, Walker RWH, et al. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry2002; 73:134-140.
25.
25. Brucke T, Podreka I, Angelberger P, et al. Dopamine-D2 receptor imaging with SPECT studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab1991; 11:220-228.
26.
26. Oyanagi C, Katsumi Y, Hanakawa T, et al. Comparison of striatal dopamine D2 receptors in Parkinson’s disease and progressive supranuclear palsy patients using I-123 iodobenzofuran single-photon emission computed tomography. J Neuroimaging2002; 12:316-324.
27.
27. Tatsch K, Schwarz J, Oertel WH, Kirsch CM. SPECT imaging of dopamine D2 receptors with I-123 IBZM: initial experience in controls and patients with Parkinson’s syndrome and Wilson’s disease. Nucl Med Commun1991; 12:699-707.
28.
28. Laulumaa V, Kuikka JT, Soininen H, Bergstrom K, Lansimies E, Riekkinen P.Imaging of D2 dopamine receptors of patients with Parkinson’s disease using single photon emission computed tomography and iodobenzamide I123. Arch Neurol1993; 50:509-512.
29.
29. Firbank MJ, Harrison RM, O’Brien JT. A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson’s disease. Dement Geriatr Cogn Disord2002; 14:64-76.
30.
30. Camicioli RM, Korzan JR, Foster SL, et al. Posterior cingulate metabolic changes occur in Parkinson’s disease patients without dementia. Neurosci Lett2004; 354:177-180.
31.
31. Elsinger CL, Rao SM, Zimbelman JL, Reynolds NC, Blindauer KA, Hoffmann RG. Neural basis for impaired time reproduction in Parkinson’s disease: an fMRI study. J Int Neuropsychol Soc2003; 9:1088-1098.
32.
32. Tambasco N, Lalli F, Rossi A, Gallai V, Guercini G, Pelliccioli GP. Activation of cortical motor areas in Parkinson’s disease: a functional magnetic resonance study. Riv Neuroradiol2000; 13:105-109.
33.
33. Haslinger B, Erhard P, Kampfe N, et al. Event-related functional magnetic resonance imaging in Parkinson’s disease before and after levodopa. Brain2001; 124:558-570.
34.
34. Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM. Cognitive impairments in early Parkinson’s disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci2003; 23:6351-6356.
35.
35. Albin RL, Minoshima S, Damato CJ, Frey KA, Kuhl DA, Sima AAF. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology1996; 47:462-466.
36.
36. Higuchi M, Tashiro M, Arai H, et al. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol2000; 162:247-256.
37.
37. Imamura T, Ishii K, Sasaki M, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease: a comparative study using positron emission tomography. Neurosci Lett1997; 235:49-52.
38.
38. Ishii K, Imamura T, Sasaki M, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease. Neurology1998; 51:125-130.
39.
39. Hu XS, Okamura N, Arai H, et al. F-18-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology2000; 55:1575-1576.
40.
40. Colloby SJ, Fenwick JD, Williams ED, et al. A comparison of Tc-99m-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer’s disease using statistical parametric mapping. Eur J Nucl Med Mol Imaging2002; 29:615-622.
41.
41. Donnemiller E, Heilmann J, Wenning GK, et al. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med1997; 24:320-325.
42.
42. Ishii K, Yamaji S, Kitagaki H, Imamura T, Hirono N, Mori E.Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology1999; 53:413-416.
43.
43. Defebvre LJ, Leduc V, Duhamel A, et al. Technetium HMPAO SPECT study in dementia with Lewy bodies, Alzheimer’s disease and idiopathic Parkinson’s disease. J Nucl Med1999; 40:956-962.
44.
44. Molina JA, Garcia-Segura JM, Benito-Leon J, et al. Proton magnetic resonance spectroscopy in dementia with Lewy bodies. Eur Neurol2002; 48:158-163.
45.
45. Burton EJ, Karas G, Paling SM, et al. Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage2002; 17:618-630.
46.
46. Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brucke T.I-123 beta-CIT and SPECT in essential tremor and Parkinson’s disease. J Neural Transm1998; 105:1213-1228.
47.
47. Marek K, Seibyl J, Holloway R, et al. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology2000; 55:1540-1547.
48.
48. Nurmi E, Ruottinen HM, Bergman J, et al. Rate of progression in Parkinson’s disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord2001; 16:608-615.
49.
49. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson’s disease. Brain1996; 119:585-591.
50.
50. Kaasinen V, Aalto S, Nagren K, Hietala J, Sonninen P, Rinne JO. Extrastriatal dopamine D-2 receptors in Parkinson’s disease: a longitudinal study. J Neural Transm2003; 110:591-601.
51.
51. Marek K, Innis R, van Dyck C, et al. I-123 beta-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology2001; 57:2089-2094.
52.
52. Pirker W, Djamshidian S, Asenbaum S, et al. Progression of dopaminergic degeneration in Parkinson’s disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord2002; 17:45-53.
53.
53. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, Wolters EC. I-123 beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease. J Neurol Neurosurg Psychiatry2003; 74:294-298.
54.
54. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol2003; 54:93-101.
55.
55. Rakshi JS, Pavese N, Uema T, et al. A comparison of the progression of early Parkinson’s disease in patients started on ropinirole or L-dopa: an F-18-dopa PET study. J Neural Transm2002; 109:1433-1443.
56.
56. Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D-1 and D-2 site binding in L-dopa-treated Parkinson’s disease patients with and without dyskinesias. Neurology1997; 49:717-723.
57.
57. Schwarz J, Tatsch K, Arnold G, et al. I-123 iodobenzamide SPECT predicts dopaminergic responsiveness in patients with denovo parkinsonism. Neurology1992; 42:556-561.
58.
58. Schwarz J, Tatsch K, Gasser T, Arnold G, Oertel WH. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy. Mov Disord1997; 12:898-902.
59.
59. Schwarz J, Tatsch K, Gasser T, et al. I-123-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord1998; 13:16-19.
